Dermata Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions.
Dermata Therapeutics stock last closed at $1.62, down 13.37% from the previous day, and has decreased 87.5% in one year. It has underperformed other stocks in the Biotechnology industry by 0.89 percentage points. Dermata Therapeutics stock is currently +65.31% from its 52-week low of $0.98, and -90.26% from its 52-week high of $16.64.
There are currently 2.34M DRMA shares outstanding. The market value of DRMA is $3.79M. In the last 24 hours, 312,029 DRMA shares were traded.
How to Buy Dermata Therapeutics Stock
Not sure how to invest in Dermata Therapeutics stock? Here's how.
Choose where to buy Dermata Therapeutics stock: You need to decide on an online brokerage, but don't worry - we've tested dozens of online stock brokerages and apps to help you choose where to buy Dermata Therapeutics stock.
Sign up for a brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
Deposit funds into your investment account: Choose your payment method and add your info.
Analyze Dermata Therapeutics stock: The Dermata Therapeutics ticker symbol is DRMA. Is Dermata Therapeutics stock a good investment? Should you buy shares of DRMA? How do DRMA's underlying business fundamentals look? Do top analysts think Dermata Therapeutics is a good buy? Why has DRMA's stock price moved recently? (Hint: Our stock research tools can help you evaluate if DRMA is a good stock to buy).
Make your DRMA buy order: Decide if you will purchase DRMA shares at the current market price or use a limit order to purchase DRMA shares at a specific price.
Keep tabs on your DRMA position: Create a watchlist to watch your position in Dermata Therapeutics stock.
Step 1: Choose where to buy Dermata Therapeutics stock
You will need a brokerage account in order to access the NASDAQ market and buy DRMA stock.
A brokerage account is an investment account that allows you to buy and sell a number of financial instruments, such as stocks, bonds, mutual funds, and ETFs.
Our recommended brokerage: eToro
Based on our experience, eToro is the best brokerage. eToro gives you:
Invest in stocks with zero commissions: Invest without paying trading commissions.
Buy fractional shares: Even if you can't afford a full share, you can still purchase the stock.
Access to world markets: From Tech to Utilities, New York to Hong Kong — you can fill your portfolio with stocks from the globe's leading stock exchanges.
Social investing: eToro has a community with more than 20 million users around the world. Talk to, learn from, and copy the unique crypto portfolios of top investors.
Security: eToro is a regulated and licensed brokerage platform.
Buy other assets: Such as ETFs and cryptos.
Get $10 towards your share purchase by creating an account with eToro now.
eToro securities trading is offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency is offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. https://www.wallstreetzen.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD.
Step 2: Sign up for a brokerage account
Now that you've picked your brokerage, you need to fill out some personal info so you are able to buy DRMA stock today.
Once you have chosen the best place to buy Dermata Therapeutics stock, it's absolutely critical to analyze their stock before you invest, so you actually wrap your head around the risk and opportunity.
Dermata Therapeutics shares data
DRMA Price
$1.62
1w %
-35.97%
1y %
-87.5%
5y %
N/A
P/E
-0.14x
P/B
0.47x
P/S
N/A
PEG
N/A
Revenue
$0.00
Earnings
-$9.06M
Fore. Rev. Growth
N/A
Fore. Earn. Growth
N/A
Market Cap
$3.79M
Next Earnings
N/A
Next Dividend
N/A
DRMA Zen Score
WallStreetZen was designed to help average investors do more in-depth fundamental analysis quickly.
Is Dermata Therapeutics stock a Buy, Hold, or Sell, according to analysts?
Out of 1 Equities analysts who track DRMA, the consensus analyst rating on DRMA is a Strong Buy
Please keep in mind that analyst forecasts are not recommendations, nor are they financial advice.
Latest DRMA Analyst Upgrades/Downgrades
Anthony Vendetti, a bottom 5% analyst from Maxim Group maintains DRMA with a strong buy rating and lowers their DRMA price target from $16.00 to $4.00, on Mar 23, 2023.
No, Dermata Therapeutics doesn't provide an income stream by paying out dividends.
DRMA Social Trading Data
One of the reasons eToro is our highest-rated brokerage is because of its social trading community.
Click below to find out what other investors have to say.
Step 5: Make your DRMA buy order
There are two primary order types:
Market order: A market order is an order to buy or sell a stock at the best price on the market. Market orders are mostly fine for most investors.
Limit order: A limit order allows you to buy or sell a stock at a specific price (or better). If you want to ensure you're buying or selling at an exact price, use a limit order.
Hit the Open Trade button and eToro will place your order.
If you require more info about buying stocks on eToro, watch the helpful video below:
How much does it cost to buy one Dermata Therapeutics share?
As of May 26, 2023, it costs $1.62 to buy one share of Dermata Therapeutics stock.
Remember, eToro's fractional share buying allows you to buy partial shares of stocks and ETFs. Even if you only have $0.81, you can buy 0.5 shares of DRMA.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.